Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P02708

UPID:
ACHA_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P02708; B4DRV6; D3DPE8

BACKGROUND:
Acetylcholine receptor subunit alpha is essential for synaptic transmission, mediating the response to acetylcholine in the neuromuscular junction. It is involved in the critical process of converting chemical signals into muscle movements, highlighting its importance in voluntary and involuntary muscle control.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Acetylcholine receptor subunit alpha could open doors to potential therapeutic strategies for treating diseases like Multiple pterygium syndrome and congenital myasthenic syndromes, where muscle function is compromised. Developing drugs targeting this receptor could revolutionize treatment options for these patients.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.